Nausea and Vomiting, PostoperativePhase 2/3NCT05658406
Supplemental Perioperative Intravenous Crystalloids for Postoperative Nausea and Vomiting in Children Undergoing Oncological Surgery
A Phase 2/3 study testing Ringer's Lactate and normal Saline in people with Nausea and Vomiting, Postoperative, run by Alexandria University at 1 site in Egypt.
Trial summary
Postoperative nausea and vomiting (PONV) is a common complication in the paediatric population and is a source of significant morbidity. The incidence of PONV in children is alarmingly high, as it is estimated to be between 33.2% to 82% depending on patient risk factors. Read more about this study
- Who is it for?
- Ages 3 to 13 years
- Conditions the study is for
- Nausea and Vomiting, Postoperative
- What is being tested?
- Ringer's Lactate and normal Saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Jan 2022to 27 Sep 2022
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 13 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- diagnosis of malignancy and undergoing surgery
Who cannot join
- They personally had a history of PONV or motion sickness;
- A sibling or parent or both, had a history of PONV.
- They received antiemetic medication in the 24 hours preceding surgery.
- Their BMI exceeded 30 kg/m2.
- They had a history of cardiovascular or renal disease.
- Developmental delay or mental retardation, or both.
- They significant intraoperative blood loss (> 30% blood volume loss)
Trial locations and contacts
1 site in 1 country.
About this study
Postoperative nausea and vomiting (PONV) is a common complication in the paediatric population and is a source of significant morbidity. The incidence of PONV in children is alarmingly high, as it is estimated to be between 33.2% to 82% depending on patient risk factors. Even with the administration of prophylactic antiemetic medications, the risk of PONV can still be approximately 30%. Various independent risk factors have been implicated in the development of paediatric PONV. The following risk factors were identified: a duration of surgery 30 minutes or longer, age 3 years or older, strabismus, adenoidectomy, and tonsillectomy surgeries, a history of PONV in the child or immediate relatives (parents or siblings), use of volatile anaesthetic, use of opioids, increased postoperative pain, prolonged preoperative fast, and state of dehydration Significant improvement in patient satisfaction can be achieved if the incidence of PONV is decreased. Although not usually life-threatening, PONV may lead to complications commonly associated with vomiting, including dehydration, electrolyte imbalance, and aspiration of gastric contents. In some surgical cases, PONV has also led to wound complications, oesophageal rupture, subcutaneous emphysema, pneumomediastinum, and bilateral pneumothorax. PONV typically describes nausea, vomiting, or retching that can occur starting in the post-anaesthesia care unit (PACU) and continuing through the 24 hours following surgery. PONV occurs twice as often in children than in adults and can lead to longer PACU stays, delays in hospital discharge and subsequent unplanned readmissions, which ultimately lead to significant financial burden on the patients.
A variety of antiemetic regimens are recommended for the prevention and treatment of PONV in children, including pharmacotherapy with dexamethasone, 5HT-3 receptor antagonists, butyrophenones, prokinetics, anticholinergics and antihistamines.
Read more
Hydration is yet another important factor in the development of PONV in paediatric patients. Administration of intravenous dextrose-containing solutions may also prevent PONV. Investigation of the effect of perioperative intravenous crystalloid administration on PONV was initially motivated by the results of observational studies suggesting that perioperative volume status influenced postoperative complication rates. This work showed that PONV was among the most prevalent events after surgery and motivated subsequent inquiry into the relationship between perioperative volume resuscitation and PONV .
Multiple reviews have explained the complex physiology of nausea and vomiting. Briefly, the vomiting centre, located in the lateral reticular formation of the medulla, co-ordinates efferent activity to the respiratory, gastrointestinal, and abdominal musculature to produce vomiting. This centre receives afferent stimuli from a variety of sites: the pharynx, gastrointestinal tract chemo- and stretch receptors, the brain (including vestibular information from cranial nerve VIII), aortic baroreceptors, and the chemoreceptor trigger zone. The chemoreceptor trigger zone is a neural centre physiologically outside of the blood-brain barrier, which provides afferent information to the vomiting centre in response to noxious stimuli in the blood.
Patients particularly paediatrics typically present for surgery with a fluid deficit secondary to fasting, bleeding, bowel preparation, and other causes of dehydration. It has been proposed that brainstem, vestibular, and intestinal hypoperfusion, with concomitant ischaemia, may mediate nausea and vomiting. Supplemental intravenous crystalloids could serve to mitigate this effect; however, no proven explanation for the putative role of volume status in this model exists. Hypovolemia has been associated with a rise in postoperative morbidity and mortality ranging from PONV to other complications such as organ dysfunction . Hypovolemia from overnight fasting without adequate fluid replacement can cause adverse effects postoperatively . Intravenous crystalloids are widely administered before, during, and after procedures requiring general anaesthesia. They are inexpensive and have relatively few adverse effects. A prior systematic review has suggested that supplemental intravenous crystalloids may be effective in preventing PONV . However, studies of supplemental perioperative intravenous crystalloids were noted to vary widely on the specific volumes administered.
Despite evidence-based, multimodal prophylactic regimens, PONV remains a prevalent clinical problem . The use of pharmacologic agents alone reduces the risk of PONV but increases the risk of side effects. Intravenous crystalloids are an attractive treatment modality. Many different intravenous fluid interventions have been tested in a wide variety of surgical and anaesthetic contexts.
Read the detailed description
The aim of this study is to test the hypothesis that intraoperative supplemental intravenous crystalloid fluid administration will reduce the incidence of postoperative nausea and vomiting in paediatric patients undergoing oncological surgical procedures under general anaesthesia.
Outcomes:
Primary outcomes:
We will analyse the risk of PONV occurring at different postoperative time points postoperatively (i.e., early, late). The early postoperative period will be defined as the period within six hours after surgery, while the late postoperative period will be defined as the time nearest to 24 hours after surgery. PON was defined as an unpleasant sensation associated with the urge to vomit. POV was defined as an attempted expulsion of gastric contents (vomiting or retching). PONV was defined as any nausea, vomiting, or both.
Secondary outcomes:
- Risk of requiring antiemetic rescue medication during the postoperative period. Antiemetic rescue medication was defined as any additional intervention provided for the treatment of established PON, POV, or PON.
- Risk of suffering a serious adverse event (any of: admission to high-dependency unit, postoperative cardiac or respiratory complication, or death).
- To comprehensively determine the predictors of PONV as the dependant variable with age, gender, weight, operative time, treatment group, pain, fever, and preoperative chemotherapy as independent variables.
Patients and methods
This double-blind, prospective randomized controlled trial will be conducted in Borg Al-Arab Children's Cancer Centre, Alexandria University Hospitals in Borg Al-Arab, Alexandria, Egypt. After obtaining ethical committee approval and informed consent, we will study 100 patients, aged 3-13 years, with a diagnosis of malignancy, undergoing surgery. Parents will be given the option to give their children clear fluids up to 4 hours prior their arrival to the operating room. Screened participants will be excluded if:
- They personally had a history of PONV or motion sickness;
- A sibling or parent or both, had a history of PONV.
- They received antiemetic medication in the 24 hours preceding surgery.
- Their BMI exceeded 30 kg/m2.
- They had a history of cardiovascular or renal disease.
- Developmental delay or mental retardation, or both.
- They significant intraoperative blood loss (> 30% blood volume loss).
- They had a history of cardiorespiratory disease.
- They had a history of renal or hepatic diseases.
Patients will be prospectively and randomly assigned to one of the four groups (25 in each group). Random sequence generation and allocation concealment will be done using Computer-generated randomization. Supplemental crystalloid administration started after induction of anaesthesia (intraoperatively), in addition to standard fluid management. Patients will be divided into 4 groups:
- Group A: intraoperative infusion of 15 mL/kg/hour Ringer's lactate.
- Group B: intraoperative infusion of 10 mL/kg/hour Ringer's lactate.
- Group C: intraoperative infusion of 6 mL/kg/hour Ringer's lactate.
- Group D: standard fluid management alone.
Perioperative management:
All children will be given midazolam at 0.5 mg/kg orally for sedation 30 min in preoperative holding area. Anaesthesia will induced with sevoflurane in oxygen. After induction a peripheral IV cannula will be inserted for intravenous access; none of the patients will receive any prophylactic antiemetic drugs. Anaesthesia will be maintained with endotracheal tube (ETT), and controlled ventilation using atracurium, sevoflurane, and oxygen. Anaesthesia will be supplemented with fentanyl 1 µg/kg during induction and a suitable regional analgesia technique for surgery. Monitoring will include electrocardiogram, blood pressure, endtidal CO2, temperature and pulse oximetry. The ETT Will be removed at the conclusion of surgery under a deep plane of anaesthesia.
Postoperative care will be standardized. Rescue antiemetics will be administered to patients if they were severely nauseated or vomited on more than one occasion using ondansetron 1-2 mg i.v., analgesia will be given to children complaining of pain using a pain scale monitoring for toddlers and young children. This will be consisted of oral analgesia (paracetamol). Perioperatively, the study investigators and postanesthesia care unit (PACU) nurses will be blinded to the allocation of the groups and the amount of fluid the subjects received.
- Conditions
- Nausea and Vomiting, Postoperative
- Being tested
- Ringer's Lactate, normal Saline
- Keywords
- Postoperative nausea and vomiting, oncological surgery
- Medical subject headings
- Postoperative Nausea and Vomiting, Vomiting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ringer's LactateDrug
infusion of 15 mL/kg/hour Ringer's lactate intraoperative
Ringer's LactateDrug
infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
Ringer's LactateDrug
infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
normal SalineDrug
standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | intraoperative infusion of 15 mL/kg/hour Ringer's lactate. Receives: Drug: Ringer's Lactate |
| Group B | Active comparator | intraoperative infusion of 10 mL/kg/hour Ringer's lactate Receives: Drug: Ringer's Lactate |
| Group C | Active comparator | intraoperative infusion of 6 mL/kg/hour Ringer's lactate. Receives: Drug: Ringer's Lactate |
| Group D | Placebo comparator | standard fluid management alone Receives: Drug: normal Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
risk of early postoperative nausea and vomiting
The early postoperative period will be defined as the period within six hours after surgery,
Measured: six hours after surgery
risk of late postoperative nausea and vomiting
late postoperative period will be defined as the time nearest to 24 hours after surgery
Measured: 24 hours after surgery
Secondary outcomes (1)
Risk of requiring anti-emetic rescue medication
need for postoperative anti-emetic rescue medication.
Measured: 24 hours after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2022
- Study start10 Jan 2022
- Primary completion5 Jul 2022
- Study completion27 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nausea and Vomiting, PostoperativeStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients will be prospectively and randomly assigned to one of the four groups (25 in each group). Random sequence generation and allocation concealment will be done using Computer-generated randomization. Supplemental crystalloid administration started after induction of anaesthesia (intraoperatively), in addition to standard fluid management. Patients will be divided into 4 groups: 1. Group A: intraoperative infusion of 15 mL/kg/hour Ringer's lactate. 2. Group B: intraoperative infusion of 10 mL/kg/hour Ringer's lactate. 3. Group C: intraoperative infusion of 6 mL/kg/hour Ringer's lactate. 4. Group D: standard fluid management alone.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05658406
- Sponsor's protocol ID
- 0305737
- Status last verified
- Sep 2022
- First submitted
- 12 Dec 2022
- Last updated
- 20 Dec 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supplemental Perioperative Intravenous Crystalloids for Postoperative Nausea and Vomiting in Children Undergoing Oncological Surgery
- ClinicalTrials.gov ID
- NCT05658406
- Acronym / sponsor ID
- 0305737
- Conditions
- Nausea and Vomiting, Postoperative
- Keywords
- Postoperative nausea and vomiting, oncological surgery
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 10 Jan 2022 (actual)
- Primary completion
- 5 Jul 2022 (actual)
- Study completion
- 27 Sep 2022 (actual)
- First posted
- 20 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postoperative nausea and vomiting (PONV) is a common complication in the paediatric population and is a source of significant morbidity. The incidence of PONV in children is alarmingly high, as it is estimated to be between 33.2% to 82% depending on patient risk factors. Even with the administration of prophylactic antiemetic medications, the risk of PONV can still be approximately 30%. Various independent risk factors have been implicated in the development of paediatric PONV. The following risk factors were identified: a duration of surgery 30 minutes or longer, age 3 years or older, strabismus, adenoidectomy, and tonsillectomy surgeries, a history of PONV in the child or immediate relatives (parents or siblings), use of volatile anaesthetic, use of opioids, increased postoperative pain, prolonged preoperative fast, and state of dehydration Significant improvement in patient satisfaction can be achieved if the incidence of PONV is decreased. Although not usually life-threatening, PONV may lead to complications commonly associated with vomiting, including dehydration, electrolyte imbalance, and aspiration of gastric contents. In some surgical cases, PONV has also led to wound complications, oesophageal rupture, subcutaneous emphysema, pneumomediastinum, and bilateral pneumothorax. PONV typically describes nausea, vomiting, or retching that can occur starting in the post-anaesthesia care unit (PACU) and continuing through the 24 hours following surgery. PONV occurs twice as often in children than in adults and can lead to longer PACU stays, delays in hospital discharge and subsequent unplanned readmissions, which ultimately lead to significant financial burden on the patients.
A variety of antiemetic regimens are recommended for the prevention and treatment of PONV in children, including pharmacotherapy with dexamethasone, 5HT-3 receptor antagonists, butyrophenones, prokinetics, anticholinergics and antihistamines.
Hydration is yet another important factor in the development of PONV in paediatric patients. Administration of intravenous dextrose-containing solutions may also prevent PONV. Investigation of the effect of perioperative intravenous crystalloid administration on PONV was initially motivated by the results of observational studies suggesting that perioperative volume status influenced postoperative complication rates. This work showed that PONV was among the most prevalent events after surgery and motivated subsequent inquiry into the relationship between perioperative volume resuscitation and PONV .
Multiple reviews have explained the complex physiology of nausea and vomiting. Briefly, the vomiting centre, located in the lateral reticular formation of the medulla, co-ordinates efferent activity to the respiratory, gastrointestinal, and abdominal musculature to produce vomiting. This centre receives afferent stimuli from a variety of sites: the pharynx, gastrointestinal tract chemo- and stretch receptors, the brain (including vestibular information from cranial nerve VIII), aortic baroreceptors, and the chemoreceptor trigger zone. The chemoreceptor trigger zone is a neural centre physiologically outside of the blood-brain barrier, which provides afferent information to the vomiting centre in response to noxious stimuli in the blood.
Patients particularly paediatrics typically present for surgery with a fluid deficit secondary to fasting, bleeding, bowel preparation, and other causes of dehydration. It has been proposed that brainstem, vestibular, and intestinal hypoperfusion, with concomitant ischaemia, may mediate nausea and vomiting. Supplemental intravenous crystalloids could serve to mitigate this effect; however, no proven explanation for the putative role of volume status in this model exists. Hypovolemia has been associated with a rise in postoperative morbidity and mortality ranging from PONV to other complications such as organ dysfunction . Hypovolemia from overnight fasting without adequate fluid replacement can cause adverse effects postoperatively . Intravenous crystalloids are widely administered before, during, and after procedures requiring general anaesthesia. They are inexpensive and have relatively few adverse effects. A prior systematic review has suggested that supplemental intravenous crystalloids may be effective in preventing PONV . However, studies of supplemental perioperative intravenous crystalloids were noted to vary widely on the specific volumes administered.
Despite evidence-based, multimodal prophylactic regimens, PONV remains a prevalent clinical problem . The use of pharmacologic agents alone reduces the risk of PONV but increases the risk of side effects. Intravenous crystalloids are an attractive treatment modality. Many different intravenous fluid interventions have been tested in a wide variety of surgical and anaesthetic contexts.
Detailed description
The aim of this study is to test the hypothesis that intraoperative supplemental intravenous crystalloid fluid administration will reduce the incidence of postoperative nausea and vomiting in paediatric patients undergoing oncological surgical procedures under general anaesthesia.
Outcomes:
Primary outcomes:
We will analyse the risk of PONV occurring at different postoperative time points postoperatively (i.e., early, late). The early postoperative period will be defined as the period within six hours after surgery, while the late postoperative period will be defined as the time nearest to 24 hours after surgery. PON was defined as an unpleasant sensation associated with the urge to vomit. POV was defined as an attempted expulsion of gastric contents (vomiting or retching). PONV was defined as any nausea, vomiting, or both.
Secondary outcomes:
- Risk of requiring antiemetic rescue medication during the postoperative period. Antiemetic rescue medication was defined as any additional intervention provided for the treatment of established PON, POV, or PON.
- Risk of suffering a serious adverse event (any of: admission to high-dependency unit, postoperative cardiac or respiratory complication, or death).
- To comprehensively determine the predictors of PONV as the dependant variable with age, gender, weight, operative time, treatment group, pain, fever, and preoperative chemotherapy as independent variables.
Patients and methods
This double-blind, prospective randomized controlled trial will be conducted in Borg Al-Arab Children's Cancer Centre, Alexandria University Hospitals in Borg Al-Arab, Alexandria, Egypt. After obtaining ethical committee approval and informed consent, we will study 100 patients, aged 3-13 years, with a diagnosis of malignancy, undergoing surgery. Parents will be given the option to give their children clear fluids up to 4 hours prior their arrival to the operating room. Screened participants will be excluded if:
- They personally had a history of PONV or motion sickness;
- A sibling or parent or both, had a history of PONV.
- They received antiemetic medication in the 24 hours preceding surgery.
- Their BMI exceeded 30 kg/m2.
- They had a history of cardiovascular or renal disease.
- Developmental delay or mental retardation, or both.
- They significant intraoperative blood loss (> 30% blood volume loss).
- They had a history of cardiorespiratory disease.
- They had a history of renal or hepatic diseases.
Patients will be prospectively and randomly assigned to one of the four groups (25 in each group). Random sequence generation and allocation concealment will be done using Computer-generated randomization. Supplemental crystalloid administration started after induction of anaesthesia (intraoperatively), in addition to standard fluid management. Patients will be divided into 4 groups:
- Group A: intraoperative infusion of 15 mL/kg/hour Ringer's lactate.
- Group B: intraoperative infusion of 10 mL/kg/hour Ringer's lactate.
- Group C: intraoperative infusion of 6 mL/kg/hour Ringer's lactate.
- Group D: standard fluid management alone.
Perioperative management:
All children will be given midazolam at 0.5 mg/kg orally for sedation 30 min in preoperative holding area. Anaesthesia will induced with sevoflurane in oxygen. After induction a peripheral IV cannula will be inserted for intravenous access; none of the patients will receive any prophylactic antiemetic drugs. Anaesthesia will be maintained with endotracheal tube (ETT), and controlled ventilation using atracurium, sevoflurane, and oxygen. Anaesthesia will be supplemented with fentanyl 1 µg/kg during induction and a suitable regional analgesia technique for surgery. Monitoring will include electrocardiogram, blood pressure, endtidal CO2, temperature and pulse oximetry. The ETT Will be removed at the conclusion of surgery under a deep plane of anaesthesia.
Postoperative care will be standardized. Rescue antiemetics will be administered to patients if they were severely nauseated or vomited on more than one occasion using ondansetron 1-2 mg i.v., analgesia will be given to children complaining of pain using a pain scale monitoring for toddlers and young children. This will be consisted of oral analgesia (paracetamol). Perioperatively, the study investigators and postanesthesia care unit (PACU) nurses will be blinded to the allocation of the groups and the amount of fluid the subjects received.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- Patients will be prospectively and randomly assigned to one of the four groups (25 in each group). Random sequence generation and allocation concealment will be done using Computer-generated randomization. Supplemental crystalloid administration started after induction of anaesthesia (intraoperatively), in addition to standard fluid management. Patients will be divided into 4 groups: 1. Group A: intraoperative infusion of 15 mL/kg/hour Ringer's lactate. 2. Group B: intraoperative infusion of 10 mL/kg/hour Ringer's lactate. 3. Group C: intraoperative infusion of 6 mL/kg/hour Ringer's lactate. 4. Group D: standard fluid management alone.
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Drug: Ringer's Lactateintraoperative infusion of 15 mL/kg/hour Ringer's lactate. |
| Group B | Active comparator | Drug: Ringer's Lactateintraoperative infusion of 10 mL/kg/hour Ringer's lactate |
| Group C | Active comparator | Drug: Ringer's Lactateintraoperative infusion of 6 mL/kg/hour Ringer's lactate. |
| Group D | Placebo comparator | Drug: normal Salinestandard fluid management alone |
Who may qualify
- Ages
- 3 to 13 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- diagnosis of malignancy and undergoing surgery
Key exclusion criteria (7 listed)
- They personally had a history of PONV or motion sickness;
- A sibling or parent or both, had a history of PONV.
- They received antiemetic medication in the 24 hours preceding surgery.
- Their BMI exceeded 30 kg/m2.
- They had a history of cardiovascular or renal disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ringer's Lactateinfusion of 15 mL/kg/hour Ringer's lactate intraoperative | Drug | Group A |
| Ringer's Lactateinfusion of 10 mL/kg/hour Ringer's lactate intraoperative . | Drug | Group B |
| Ringer's Lactateinfusion of 6 mL/kg/hour Ringer's lactate intraoperative . | Drug | Group C |
| normal Salinestandard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight | Drug | Group D |
Primary outcome
risk of early postoperative nausea and vomiting
Time frame: six hours after surgery
The early postoperative period will be defined as the period within six hours after surgery,
risk of late postoperative nausea and vomiting
Time frame: 24 hours after surgery
late postoperative period will be defined as the time nearest to 24 hours after surgery
1 secondary outcome
Risk of requiring anti-emetic rescue medication
Time frame: 24 hours after surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2022.
- Individual participant dataSharing planned: No
Related trials for Nausea and Vomiting, Postoperative
Not yet recruitingObservational study
Preoperative Gastric Volume and PONV in Pediatric Appendectomy Cases
Postoperative Nausea and Vomiting
Not yet recruiting
Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery
PONV
Not yet recruiting
Binaural Beats and Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy
Laparoscopic Cholecystectomy
Active, not recruiting
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
Postoperative Nausea, Postoperative Vomiting
Active, not recruitingPhase 4
A Randomized Controlled Trial Comparing the Effects of Different Anesthetic Sedatives on PONV in Laparoscopic Cholecystectomy
Cholelithiasis, Postoperative Nausea and Vomiting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Ringer's Lactate and normal Saline in people with Nausea and Vomiting, Postoperative, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
risk of early postoperative nausea and vomiting (time frame: six hours after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2022.